A. Noble

发表

Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: clinical application using only one blood sample.

J. Catalin, F. Leca, D. Marchiset-Leca, 1998, Anti-cancer drugs.

Dose Individualization of Carboplatin After a 120-hour Infusion Schedule: Higher Dose Intensity but Fewer Toxicities

M. Baciuchka, B. Lacarelle, P. Guillet, 2006, Therapeutic drug monitoring.

Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics

J. Catalin, F. Leca, D. Marchiset-Leca, 2004, Cancer Chemotherapy and Pharmacology.

A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference

S. Dilly, D. Cupissol, L. Goedhals, 1994 .

A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group.

S. Dilly, D. Cupissol, L. Goedhals, 1994, European journal of cancer.

A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans

A. Iliadis, F. Leca, D. Marchiset-Leca, 2004, Cancer Chemotherapy and Pharmacology.

A double-blind, randomized, parallel study of IV dolasetron mesilate versus IV metoclopramide in patients receiving moderately emetogenic chemotherapy

D. Spaeth, D. Cupissol, M. Fabbro, 1996 .

New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol

F. Leca, A. Noble, M. Antonetti, 1991, European Journal of Drug Metabolism and Pharmacokinetics.

P803 Plasma N-glycan biomarkers predict patient Response to Vedolizumab treatment for Crohn’s Disease

J. Satsangi, G. D'Haens, A. L. Li Yim, 2023, Journal of Crohn's and Colitis.

Addressing educational gaps through multidisciplinary team education in eosinophilic oesophagitis management

A. Bredenoord, J. Spergel, I. Skypala, 2023, Journal of CME.